ReviewCurrent oncology reports2026
An Update on Treatments for Recurrent Primary Central Nervous System Lymphoma.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Translating advances in primary central nervous system lymphoma: from prognostic stratification to treatment innovation.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewRecurrent primary central nervous system lymphoma (PCNSL) has remained a challenging disease to treat with high rates of relapse with relatively short remissions. The purpose of this review was to assess the current landscape of treatment for recurrent PCNSL. RECENT
findingsClinical trials have investigated treatments including methotrexate regimens, Bruton’s tyrosine kinase inhibitors, immunomodulatory drugs, immune checkpoint inhibitors, CAR-T, IRAK4 inhibitors, bispecific antibodies, and other targeted agents. Despite significant overall response rates (ORR), most studies yielded short nondurable remissions. More recent trials have therefore pursued combination of these novel agents. Preliminary data from selected active trials for recurrent PCNSL have indicated notable ORRs ranging from 50 to 94% and tolerable safety profiles. Novel treatments have shown promise in treatment for recurrent PCNSL, significantly increasing available options at recurrence. Due to nondurable monotherapy responses, combination therapy of investigational agents has emerged as a consensus path forward for future clinical trials.
Indexed as
Identifiers
41758412What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.